Epstein-Barr virus antigens (EBV antigens) (EBV antigens)

Epstein-Barr virus (EBV) antigens, primarily including Latent Membrane Proteins (LMP1, LMP2) and Epstein-Barr Nuclear Antigens (EBNA1, EBNA2, EBNA3 series), are the primary targets for immunotherapies aimed at treating EBV-associated malignancies (Source: UniProt, P03211, P03230). These antigens are expressed in various patterns during viral latency and are essential for the transformation and survival of B cells and epithelial cells, leading to diseases such as nasopharyngeal carcinoma, Hodgkin lymphoma, and post-transplant lymphoproliferative disorder (PTLD) (Source: PubMed, PMID: 31434064). The therapeutic strategy of targeting these antigens via native T-cell receptors (TCRs) utilizes the natural ability of T cells to recognize intracellular viral peptides presented by Major Histocompatibility Complex (MHC) molecules (Source: Nature Reviews Clinical Oncology, 2020). Unlike CAR-T cells, which typically target surface proteins, TCR-based therapies can access the full range of EBV-derived proteins, providing a broader array of potential targets (Source: NIH, ClinicalTrials.gov). Current clinical developments include adoptive cell therapies like Tabelecleucel (Ebvallo), which consists of allogeneic EBV-specific T cells that recognize these antigens to eliminate EBV-positive tumor cells in immunocompromised patients (Source: EMA, Ebvallo Assessment Report). The success of these therapies is highly dependent on the patient's HLA type, as the native TCR must match the MHC-peptide complex presented by the target cells (Source: Journal of Clinical Oncology, 2022). Monitoring efficacy typically involves measuring EBV DNA viral load and assessing the expression of specific latent antigens within the tumor microenvironment (Source: Blood, 2019). Safety concerns primarily involve potential cytokine release syndrome and the risk of graft-versus-host disease in allogeneic settings, alongside the challenge of immune evasion through antigen downregulation (Source: Frontiers in Immunology, 2021).

Other names

EBV-associated antigensEpstein-Barr virus proteinsEBNALMPEBV-Ag

T-cell mediated cytotoxicity via MHC-restricted antigen recognition